Skip to main content
HUMA
NASDAQ Life Sciences

Humacyte 公布Q4亏损幅度大于预期，运营和净利润估计偏差

feedReported by Reuters
Sentiment info
Negative
Importance info
8
Price
$0.782
Mkt Cap
$150.228M
52W Low
$0.701
52W High
$2.93
Market data snapshot near publication time

summarizeSummary

Humacyte 公布的Q4业绩明显低于分析师预期，运营收入为-$30.836百万，而预计为-$22.8百万，净利润为-$24.804百万，与预计的-$23.3百万相比。这种大于预期的亏损表明燃烧率较高，这是小型生物技术公司的一个重大问题。该消息紧随上周2000万美元直接注册发行之后，这已经造成了稀释。持续的财务业绩不佳可能会对股票施加更大的压力，使即将到来的产品开发和监管里程碑（如最近在以色列提交的MAA申请）对于投资者信心更加至关重要。

在该公告发布时，HUMA的交易价格为$0.78，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1.5亿。 52周交易区间为$0.70至$2.93。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed HUMA - Latest Insights

HUMA
Apr 28, 2026, 4:52 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Humacyte Seeks Shareholder Approval to Increase Authorized Shares by 200 Million, Paving Way for Future Capital Raises
Sentiment: Neutral
View Wiseek Article
HUMA
Apr 24, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
7
Humacyte Reclaims Global Commercial Rights for Symvess from Fresenius
Sentiment: Positive
View Wiseek Article
HUMA
Apr 21, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Israeli Ministry of Health Accepts Humacyte's Symvess MAA, Initiating 180-Day Review
Sentiment: Positive
View Wiseek Article
HUMA
Apr 17, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Humacyte Seeks Shareholder Approval to Increase Authorized Shares by 200 Million, Paving Way for Significant Future Dilution
Sentiment: Negative
View Wiseek Article
HUMA
Mar 27, 2026, 4:45 PM EDT
Filing Type: 10-K
Importance Score:
9
Humacyte Issues Going Concern Warning Amidst Low Revenue and Dilutive Financing
Sentiment: Negative
View Wiseek Article
HUMA
Mar 27, 2026, 7:00 AM EDT
Source: Reuters
Importance Score:
8
Humacyte Reports Wider-Than-Expected Q4 Losses, Missing Operating and Net Income Estimates
Sentiment: Negative
View Wiseek Article
HUMA
Mar 19, 2026, 4:33 PM EDT
Filing Type: 8-K
Importance Score:
8
Humacyte Prices $20M Registered Direct Offering at Discount, Securing Capital for Operations
Sentiment: Negative
View Wiseek Article
HUMA
Mar 19, 2026, 4:26 PM EDT
Filing Type: 424B3
Importance Score:
9
Humacyte Finalizes $20M Offering at Deep Discount, Discloses Substantial Doubt About Going Concern
Sentiment: Negative
View Wiseek Article
HUMA
Mar 19, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
$20M Registered Direct Offering Priced by Humacyte, Signaling Share Dilution
Sentiment: Negative
View Wiseek Article
HUMA
Mar 19, 2026, 8:25 AM EDT
Filing Type: 8-K
Importance Score:
8
Humacyte Halts $60M ATM Offering, Secures Saudi Arabia Deal, and Files for Israeli Approval
Sentiment: Positive
View Wiseek Article